Analysts Expect Breakeven For THC Biomed Intl Ltd. (CSE:THC) Before Long

By
Simply Wall St
Published
April 06, 2021
CNSX:THC
Source: Shutterstock

With the business potentially at an important milestone, we thought we'd take a closer look at THC Biomed Intl Ltd.'s (CSE:THC) future prospects. THC Biomed Intl Ltd. produces and sells medical and recreational cannabis in Canada. The company’s loss has recently broadened since it announced a CA$162k loss in the full financial year, compared to the latest trailing-twelve-month loss of CA$4.6m, moving it further away from breakeven. The most pressing concern for investors is THC Biomed Intl's path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

See our latest analysis for THC Biomed Intl

Expectations from some of the Canadian Pharmaceuticals analysts is that THC Biomed Intl is on the verge of breakeven. They anticipate the company to incur a final loss in 2021, before generating positive profits of CA$1.1b in 2022. Therefore, the company is expected to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 166%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

earnings-per-share-growth
CNSX:THC Earnings Per Share Growth April 6th 2021

Given this is a high-level overview, we won’t go into details of THC Biomed Intl's upcoming projects, however, keep in mind that by and large pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

One thing we’d like to point out is that The company has managed its capital judiciously, with debt making up 34% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of THC Biomed Intl which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at THC Biomed Intl, take a look at THC Biomed Intl's company page on Simply Wall St. We've also compiled a list of essential aspects you should look at:

  1. Valuation: What is THC Biomed Intl worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether THC Biomed Intl is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on THC Biomed Intl’s board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

When trading THC Biomed Intl or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.